Microplastics and Endocrine Disruptors

These are the exposures our generation will be evaluating clinically for the next thirty years. The biology is documented. The clinical practice is just beginning to catch up.

What patients tell us

“I'm seeing more and more about microplastics in the news. Tap water, bottled water, food packaging. I have hormonal symptoms that don't fit a clear diagnosis, metabolic changes, and I'm wondering whether everyday exposures are part of what's happening.”

What this exposure category covers

Microplastics and endocrine-disrupting chemicals represent a class of environmental exposures whose health implications are being characterized in real time. The category includes microplastic particles (fragments smaller than 5 mm, including the smaller nanoplastic fraction); the chemical additives in plastics including phthalates and bisphenols (BPA, BPS, BPF); per- and polyfluoroalkyl substances (PFAS, the 'forever chemicals'); flame retardants; and various plasticizers and stabilizers that leach from consumer products into food, water, and air.

These exposures are unique in their ubiquity. Microplastics have been documented in human blood, placenta, lung tissue, breast milk, and most other tissues examined. Phthalate metabolites are detectable in urinary samples from the vast majority of the US population. PFAS contamination of drinking water affects millions of Americans.

The biology that's documented

Endocrine disruption is the most established mechanism. Phthalates, bisphenols, and many other endocrine disruptors interact with hormone receptors, particularly estrogen and androgen receptors, at doses far below those required for traditional toxicology endpoints. Certain compounds are classified as obesogens — compounds that promote adipogenesis and contribute to insulin resistance. Microplastics themselves can cross biological barriers, generate oxidative stress, and trigger inflammatory responses. PFAS compounds have been associated with thyroid dysfunction, dyslipidemia, liver effects, immune modulation, certain cancers, and metabolic effects.

How iHeal evaluates these exposures

Direct biological testing for many endocrine disruptors and PFAS compounds is available through specialty laboratories. Urinary phthalate metabolite testing identifies recent exposure patterns; PFAS testing in serum measures the major perfluorinated compounds. The interpretive limitation is that population-level exposure is so widespread that finding these compounds doesn't necessarily establish them as the primary driver of an individual patient's symptoms — clinical correlation is essential.

The intervention strategy emphasizes exposure reduction far more than treatment to remove what's already accumulated. Reducing ongoing exposure through water filtration (reverse osmosis is most effective for PFAS and most contaminants), food packaging changes, personal care product changes, and household environment changes is the foundation.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

Direct biological testing for many endocrine disruptors and PFAS compounds is available through specialty laboratories. Urinary phthalate metabolite testing identifies recent exposure patterns; PFAS testing in serum measures the major perfluorinated compounds. The interpretive limitation is that population-level exposure is so widespread that finding these compounds doesn't necessarily establish them as the primary driver of an individual patient's symptoms — clinical correlation is essential.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether microplastics and endocrine disruptors is actually contributing to your symptoms — and what to do about it.

On This Page

Microplastics and Endocrine Disruptors

These are the exposures our generation will be evaluating clinically for the next thirty years. The biology is documented. The clinical practice is just beginning to catch up.

What patients tell us

“I'm seeing more and more about microplastics in the news. Tap water, bottled water, food packaging. I have hormonal symptoms that don't fit a clear diagnosis, metabolic changes, and I'm wondering whether everyday exposures are part of what's happening.”

What this exposure category covers

Microplastics and endocrine-disrupting chemicals represent a class of environmental exposures whose health implications are being characterized in real time. The category includes microplastic particles (fragments smaller than 5 mm, including the smaller nanoplastic fraction); the chemical additives in plastics including phthalates and bisphenols (BPA, BPS, BPF); per- and polyfluoroalkyl substances (PFAS, the 'forever chemicals'); flame retardants; and various plasticizers and stabilizers that leach from consumer products into food, water, and air.

These exposures are unique in their ubiquity. Microplastics have been documented in human blood, placenta, lung tissue, breast milk, and most other tissues examined. Phthalate metabolites are detectable in urinary samples from the vast majority of the US population. PFAS contamination of drinking water affects millions of Americans.

The biology that's documented

Endocrine disruption is the most established mechanism. Phthalates, bisphenols, and many other endocrine disruptors interact with hormone receptors, particularly estrogen and androgen receptors, at doses far below those required for traditional toxicology endpoints. Certain compounds are classified as obesogens — compounds that promote adipogenesis and contribute to insulin resistance. Microplastics themselves can cross biological barriers, generate oxidative stress, and trigger inflammatory responses. PFAS compounds have been associated with thyroid dysfunction, dyslipidemia, liver effects, immune modulation, certain cancers, and metabolic effects.

How iHeal evaluates these exposures

Direct biological testing for many endocrine disruptors and PFAS compounds is available through specialty laboratories. Urinary phthalate metabolite testing identifies recent exposure patterns; PFAS testing in serum measures the major perfluorinated compounds. The interpretive limitation is that population-level exposure is so widespread that finding these compounds doesn't necessarily establish them as the primary driver of an individual patient's symptoms — clinical correlation is essential.

The intervention strategy emphasizes exposure reduction far more than treatment to remove what's already accumulated. Reducing ongoing exposure through water filtration (reverse osmosis is most effective for PFAS and most contaminants), food packaging changes, personal care product changes, and household environment changes is the foundation.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

Direct biological testing for many endocrine disruptors and PFAS compounds is available through specialty laboratories. Urinary phthalate metabolite testing identifies recent exposure patterns; PFAS testing in serum measures the major perfluorinated compounds. The interpretive limitation is that population-level exposure is so widespread that finding these compounds doesn't necessarily establish them as the primary driver of an individual patient's symptoms — clinical correlation is essential.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether microplastics and endocrine disruptors is actually contributing to your symptoms — and what to do about it.

On This Page